In vitro platelet antiaggregatory properties of 4-methylcoumarins

Biochimie

Volumn 94, Issue 12, 2012, Pages 2681-2686

  MacÁková, Kateřina ^a   Řeháková, Zuzana ^a   Mladěnka, Přemysl ^a   Karlíčková, Jana ^a   Filipský, Tomáš ^a   Říha, Michal ^a   Prasad, Ashok K ^b   Parmar, Virinder S ^b   Jahodář, Luděk ^a   Pávek, Petr ^a   Hrdina, Radomír ^a   Saso, Luciano ^c  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF DELHI   (India)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acetylsalicylic acid; Antiaggregatory; Arachidonic acid; Coumarins; Platelet

Indexed keywords

3 ETHOXYCARBONYLETHYL 5,7 DIACETOXY 4 METHYLCOUMARIN; 4 HYDROXYCOUMARIN; 4 METHYLESCULETIN; 5,7 DIHYDROXY 4 METHYLCOUMARIN; 5,7 DIMETHOXY 4 METHYLCOUMARIN; 7,8 DIACETOXY 4 METHYLCOUMARIN; 7,8 DIHYDROXY 4 METHYLCOUMARIN; 7,8 DIMETHOXY 4 METHYLCOUMARIN; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; COUMARIN DERIVATIVE; CYCLOOXYGENASE 1; HALOXON; SCOPOLETIN; THROMBOXANE A2 RECEPTOR; THROMBOXANE SYNTHASE; UMBELLIFERONE; UNCLASSIFIED DRUG; 5,7-DIHYDROXY-4-METHYLCOUMARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; UMBELLIFERONE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPOPHILICITY; THROMBOCYTE AGGREGATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY;

ADENOSINE DIPHOSPHATE; ANTICOAGULANTS; ARACHIDONIC ACID; ASPIRIN; COLLAGEN; COUMARINS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE-A SYNTHASE; UMBELLIFERONES;

EID: 84868202354     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.09.006     Document Type: Article

References (42)

1. H.B. Burchell Editorial: pathogenesis of myocardial infarction (culpable clot?) Am. J. Cardiol. 34 1974 868 869
2. S. Coccheri Antiplatelet drugs-do we need new options? with a reappraisal of direct thromboxane inhibitors Drugs 70 2010 887 908
3. P.M. Ridker, N.R. Cook, and I.M. Lee A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women New Engl. J. Med. 352 2005 1293 1304
4. D.J. Angiolillo Variability in responsiveness to oral antiplatelet therapy Am. J. Cardiol. 103 2009 27A 34A
5. D.J. Angiolillo, P. Capranzano, and S. Goto A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur. Heart J. 29 2008 2202 2211
6. Y. Chen, T. Wang, K. Lee, C. Tzeng, Y. Chang, and C. Teng Synthesis of coumarin derivatives as inhibitors of platelet aggregation Helv. Chim. Acta 79 1996 651 657 (Pubitemid 26169769)
7. G. Leoncini, M.G. Signorello, D. Bruzzese, M. Di Braccio, G.C. Grossi, and G. Roma Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414) Biochem. Pharmacol. 67 2004 911 918 (Pubitemid 38201636)
8. P. Mladenka, L. Zatloukalova, T. Filipsky, and R. Hrdina Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity Free Radic. Biol. Med. 49 2010 963 975
9. T. Wang, Y. Chen, C. Tzeng, S. Liou, Y. Chang, and C. Teng Antiplatelet α-methylidene-γ-butyrolactones: synthesis and evaluation of quinoline, flavone, and xanthone derivatives Helv Chim. Acta 79 1996 1620 1626
10. J.Z. Pedersen, C. Oliveira, and S. Incerpi Antioxidant activity of 4-methylcoumarins J. Pharm. Pharmacol. 59 2007 1721 1728 (Pubitemid 350221816)
11. R.P. Robertson Antioxidant drugs for treating beta-cell oxidative stress in type 2 diabetes: glucose-centric versus insulin-centric therapy Discov. Med. 9 2010 132 137
12. M.K. Misra, M. Sarwat, P. Bhakuni, R. Tuteja, and N. Tuteja Oxidative stress and ischemic myocardial syndromes Med. Sci. Monit. 15 2009 RA209 219
13. F. Cervenka, V. Koleckar, and Z. Rehakova Evaluation of natural substances from Evolvulus alsinoides L. with the purpose of determining their antioxidant potency J. Enzym. Inhib. Med. Chem. 23 2008 574 578
14. V.S. Parmar, S. Singh, and P.M. Boll Carbon-13 nuclear magnetic resonance spectroscopy of 4-methylcoumarins (4-methyl-2H-1-benzopyran-2-ones) Mag Res. Chem. 26 1988 430 433
15. J. O'Brien Platelet aggregation: part II some results from a new method of study J. Clin. Pathol. 15 1962 452 455
16. G.V. Born Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 1962 927 929
17. T.S. Chang, H.M. Kim, and K.S. Lee Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4- naphthalenedione (NQ-Y15) in rat platelets Biochem. Pharmacol. 54 1997 259 268
18. Cayman Chemical Company Thromboxane B2 EIA Kit 19.4.2012 http://www.caymanchem.com/app/template/Product.vm/catalog/519031
19. Cayman Chemical Company COX Inhibitor Screening Assay Kit 1.6.2012 http://www.caymanchem.com/app/template/Product.vm/catalog/560131
20. S.H. Tzeng, W.C. Ko, F.N. Ko, and C.M. Teng Inhibition of platelet aggregation by some flavonoids Thromb. Res. 64 1991 91 100
21. C.A. Kontogiorgis, K. Savvoglou, and D.J. Hadjipavlou-Litina Antiinflammatory and antioxidant evaluation of novel coumarin derivatives J. Enzym. Inhib. Med. Chem. 21 2006 21 29 (Pubitemid 43884197)
22. I. Manolov, C. Maichle-Moessmer, and N. Danchev Synthesis, structure, toxicological and pharmacological investigations of 4-hydroxycoumarin derivatives Eur. J. Med. Chem. 41 2006 882 890 (Pubitemid 44015978)
23. F. Borges, F. Roleira, N. Milhazes, L. Santana, and E. Uriarte Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity Curr. Med. Chem. 12 2005 887 916 (Pubitemid 40443846)
24. I. Kostova Synthetic and natural coumarins as antioxidants Mini Rev. Med. Chem. 6 2006 365 374
25. K.C. Fylaktakidou, D.J. Hadjipavlou-Litina, K.E. Litinas, and D.N. Nicolaides Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities Curr. Pharm. Des. 10 2004 3813 3833 (Pubitemid 39409872)
26. J.R. Hoult, and M. Paya Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential Gen. Pharmacol. 27 1996 713 722 (Pubitemid 26233347)
27. I.S. Chen, Y.C. Lin, and I.L. Tsai Coumarins and anti-platelet aggregation constituents from Zanthoxylum schinifolium Phytochemistry 39 1995 1091 1097
28. S. Vilar, E. Quezada, and L. Santana Design, synthesis, and vasorelaxant and platelet antiaggregatory activities of coumarin-resveratrol hybrids Bioorg. Med. Chem. Lett. 16 2006 257 261 (Pubitemid 41680608)
29. Y.C. Chia, F.R. Chang, and J.C. Wang Antiplatelet aggregation coumarins from the leaves of Murraya omphalocarpa Molecules 13 2008 122 128
30. I.L. Tsai, M.F. Wun, C.M. Teng, T. Ishikawa, and I.S. Chen Anti-platelet aggregation constituents from formosan Toddalia asiatica Phytochemistry 48 1998 1377 1382 (Pubitemid 28368745)
31. G. Roma, M.D. Braccio, and A. Carrieri Coumarin, chromone, and 4(3H)-pyrimidinone novel bicyclic and tricyclic derivatives as antiplatelet agents: synthesis, biological evaluation, and comparative molecular field analysis Bioorg. Med. Chem. 11 2003 123 138 (Pubitemid 35430129)
32. C.M. Teng, H.L. Li, T.S. Wu, S.C. Huang, and T.F. Huang Antiplatelet actions of some coumarin compounds isolated from plant sources Thromb. Res. 66 1992 549 557
33. V. Parmar, H. Jha, S. Sanduja, and R. Sanduja Trigocoumarin - a new coumarin from Trigonella foenumgraecum Z. Naturforsch. 37B 1981 521
34. V. Parmar, J. Rathore, S. Singh, A. Jain, and S. Gupta Troupin, a 4-methylcoumarin from Tamarix troupii Phytochemistry 24 1985 871 872
35. L. Fernyhough, S.W. Kell, A.H. Hammond, N.W. Thomas, and J.R. Fry Comparison of in vivo and in vitro rat hepatic toxicity of coumarin and methyl analogues, and application of quantitative morphometry to toxicity in vivo Toxicology 88 1994 113 125 (Pubitemid 24147701)
36. B.G. Lake, T.J. Gray, J.G. Evans, D.F. Lewis, J.A. Beamand, and K.L. Hue Studies on the mechanism of coumarin-induced toxicity in rat hepatocytes: comparison with dihydrocoumarin and other coumarin metabolites Toxicol. Appl. Pharmacol. 97 1989 311 323 (Pubitemid 19079059)
37. J. Fentema, A. Hammonda, M. Garlea, and J. Fry Toxicity of coumarin and various methyl derivatives in cultures of rat hepatocytes and V79 cells Toxicol. In Vitro 6 1992 21 25
38. M. Di Braccio, G. Grossi, G. Roma, M. Grazia Signorello, and G. Leoncini Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins Eur. J. Med. Chem. 39 2004 397 409 (Pubitemid 38526357)
39. W.R. Surin, M.K. Barthwal, and M. Dikshit Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis Thromb. Res. 122 2008 786 803
40. S. Chakrabarti, and J.E. Freedman Dipyridamole, cerebrovascular disease, and the vasculature Vascul Pharmacol. 48 2008 143 149
41. G. Roma, M. Di Braccio, and G. Grossi Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site J. Med. Chem. 50 2007 2886 2895 (Pubitemid 46980859)
42. A. Gupta, N. Priya, and S. Jalal Specificity of calreticulin transacetylase to acetoxy derivatives of benzofurans: effect on the activation of platelet nitric oxide synthase Biochimie 92 2010 1180 1185